On the Record · United Therapeutics
United Therapeutics competitors, on the record
The companies United Therapeutics itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who United Therapeutics names
| Company | Named in |
|---|---|
| Actavis | 2025 |
| ANI | 2025 |
| Apeiron Biologics AG | 2025 |
| Boehringer Ingelheim | 2025 |
| Insmed Incorporated | 2025 |
| Liquidia | 2025 |
| Merck | 2025 |
| Watson | 2025 |
In its own words
Actavis, ANI
Word for word“Under the settlement agreements, Actavis and ANI can market their generic versions of Orenitram in the United States beginning in June 2027 and December 2027, respectively, although either or both of them may be permitted to enter the market earlier under certain circumstances.” 10-K for 2025
Apeiron Biologics AG
Word for word“Unituxin may face competition from Qarziba ® (dinutuximab beta), an antibody product developed by Apeiron Biologics AG that is approved in Europe to treat high-risk neuroblastoma but is not approved in the United States.” 10-K for 2025
Boehringer Ingelheim
Word for word“There are also three therapies approved for the treatment of IPF, including Boehringer Ingelheim’s Jascayd® (nerandomilast), which was approved by FDA in October 2025 for IPF, and later for PPF.” 10-K for 2025
Insmed Incorporated
Word for word“Additional treatments, such as Insmed Incorporated’s TPIP, are in late-stage clinical trials for treatment of PAH and/or PH-ILD.” 10-K for 2025
Liquidia
Word for word“In addition, in June 2025 Liquidia launched U.S. sales of Yutrepia for PAH and PH-ILD, which now competes with our treprostinil-based products.” 10-K for 2025
Merck
Word for word“For example, Merck commercially launched Winrevair (sotatercept-csrk) in the United States in March 2024, which competes with our treprostinil-based products.” 10-K for 2025
Watson
Word for word“We have also entered into a settlement agreement with Watson permitting it to launch a generic version of Nebulized Tyvaso in the United States as early as January 2026, although to date Watson has not received FDA approval to do so.” 10-K for 2025
Read from United Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.